Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Immune Checkpoint Inhibitor Versus Observation in Patients With Completely Resected Non-Small Cell Lung Cancer at High Risk of Recurrence After Neoadjuvant Immunochemotherapy: A Multicenter, Randomized, Open-Label, Phase II Trial

NCT07748325 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT07748325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Immune Checkpoint Inhibitor Versus Observation in Patients With Completely Resected Non-Small Cell Lung Cancer at High Risk of Recurrence After Neoadjuvant Immunochemotherapy: A Multicenter, Randomized, Open-Label, Phase II Trial
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 30, 2028
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, immune checkpoint inhibitors, non-small cell lung cancer